Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CYBN Cybin	$7.17 -5.7%	$7.93	$4.81 ▼ $13.88	$169.14M	0.68	315,157 shs	468,563 shs
PHAR Pharming Group	$11.38 +1.2%	$10.88	$6.73 ▼ $17.08	$779.70M	0.02	5,997 shs	10,139 shs
REPL Replimune Group	$5.35 +5.1%	$8.42	$2.68 ▼ $17.00	$417.62M	0.67	4.10 million shs	3.04 million shs
SANA Sana Biotechnology	$3.43 +3.0%	$3.54	$1.26 ▼ $7.30	$773.39M	1.9	5.97 million shs	4.43 million shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CYBN Cybin	-0.39%	+1.88%	+1.74%	+15.85%	+1,959.62%
PHAR Pharming Group	-0.44%	-8.46%	+8.70%	+23.22%	+51.62%
REPL Replimune Group	-2.95%	-7.36%	-54.83%	-29.53%	-47.64%
SANA Sana Biotechnology	+6.59%	-22.00%	-21.45%	+93.86%	-32.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CYBN Cybin	2.0019 of 5 stars	3.6	0.0	0.0	0.6	0.8	1.3
PHAR Pharming Group	2.2545 of 5 stars	3.5	3.0	0.0	2.5	0.0	0.6
REPL Replimune Group	4.4821 of 5 stars	4.2	2.0	4.5	2.2	2.5	0.6
SANA Sana Biotechnology	3.3447 of 5 stars	3.5	3.0	0.0	3.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CYBN Cybin	3.25	Buy	$85.00	1,085.50% Upside
PHAR Pharming Group	3.00	Buy	$30.00	163.62% Upside
REPL Replimune Group	2.33	Hold	$7.67	43.30% Upside
SANA Sana Biotechnology	3.00	Buy	$8.00	133.24% Upside

Current Analyst Ratings Breakdown

Latest CYBN, REPL, PHAR, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
7/23/2025	REPL Replimune Group	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$17.00 ➝ $3.00
7/23/2025	REPL Replimune Group	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Underperform	$27.00 ➝ $2.00
7/23/2025	REPL Replimune Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/22/2025	REPL Replimune Group	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/22/2025	REPL Replimune Group	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$31.00 ➝ $6.00
7/22/2025	REPL Replimune Group	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$21.00 ➝ $3.00
7/22/2025	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$19.00 ➝ $9.00
7/22/2025	REPL Replimune Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$3.00
7/8/2025	CYBN Cybin	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$73.00 ➝ $70.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CYBN Cybin	N/A	N/A	N/A	N/A	$10.83 per share	N/A
PHAR Pharming Group	$339.84M	2.29	$0.07 per share	152.44	$3.50 per share	3.25
REPL Replimune Group	N/A	N/A	N/A	N/A	$4.31 per share	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CYBN Cybin	-$57.88M	-$3.88	N/A	N/A	N/A	N/A	-37.58%	-36.59%	N/A
PHAR Pharming Group	-$11.84M	-$0.13	N/A	379.33	N/A	-2.19%	-3.31%	-1.78%	10/23/2025 (Estimated)
REPL Replimune Group	-$247.30M	-$3.24	N/A	N/A	N/A	N/A	-69.34%	-52.81%	8/14/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$1.06	N/A	N/A	N/A	N/A	-91.96%	-43.07%	8/14/2025 (Estimated)

Latest CYBN, REPL, PHAR, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	-$0.16	+$0.04	-$0.39	N/A	N/A
8/7/2025	Q1 2026	REPL Replimune Group	-$0.83	-$0.95	-$0.12	-$0.95	$0.50 million	N/A
7/31/2025	Q2 2025	PHAR Pharming Group	-$0.10	$0.06	+$0.16	$0.06	$70.36 million	$93.20 million
5/22/2025	Q4 2025	REPL Replimune Group	-$0.75	-$0.82	-$0.07	-$0.82	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CYBN Cybin	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CYBN Cybin	N/A	24.24	24.24
PHAR Pharming Group	0.38	2.79	2.07
REPL Replimune Group	0.21	6.94	7.95
SANA Sana Biotechnology	N/A	2.47	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CYBN Cybin	17.94%
PHAR Pharming Group	0.03%
REPL Replimune Group	92.53%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
CYBN Cybin	15.00%
PHAR Pharming Group	2.07%
REPL Replimune Group	5.20%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CYBN Cybin	50	23.59 million	17.96 million	Not Optionable
PHAR Pharming Group	280	68.52 million	67.10 million	Not Optionable
REPL Replimune Group	210	78.06 million	74.00 million	Optionable
SANA Sana Biotechnology	380	225.48 million	157.61 million	Optionable

CYBN, REPL, PHAR, and SANA Headlines

Recent News About These Companies

Sana Biotechnology drops Washington plant build-out, pivots to CDMOs instead

4 hours ago | fiercepharma.comF

Sana Biotechnology Reports Non-Cash Impairment Losses

August 14 at 3:26 AM | theglobeandmail.com

Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Target Price at $8.00

August 14 at 2:15 AM | americanbankingnews.com

Sana Biotech Bails on Factory in Old AT&T Call Center

August 12 at 9:51 PM | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Beats Estimates By $0.04 EPS

August 12 at 9:25 PM | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Average Rating of "Buy" by Brokerages

August 12 at 3:22 AM | marketbeat.com

Sana: Q2 Earnings Snapshot

August 11 at 9:47 PM | sfgate.com

Sana suspends build-out of Bothell manufacturing facility

August 11 at 9:47 PM | bizjournals.com

Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates

August 11 at 4:46 PM | manilatimes.netM

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

August 8, 2025 | seekingalpha.com

Sana Biotechnology (NASDAQ:SANA) Shares Gap Down - Here's What Happened

August 8, 2025 | marketbeat.com

Seattle biotech firm Sana Biotechnology raising $75 million through public offering

August 8, 2025 | bizjournals.com

Sana Biotechnology stock tumbles after pricing public offering

August 7, 2025 | investing.com

Sana Biotechnology 20.9M share Spot Secondary priced at $3.35

August 7, 2025 | msn.com

Sana Biotechnology Shares Tumble on Pricing of Public Offering

August 7, 2025 | marketwatch.com

Sana Biotechnology (SANA) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

Sana Biotechnology Announces Pricing of Public Offering

August 6, 2025 | globenewswire.com

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

August 6, 2025 | tmcnet.com

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

August 6, 2025 | globenewswire.com

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 6, 2025 | globenewswire.com

Novel T1D Therapy Opens the Door to Cell Transplants Sans Immunosuppressants

August 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CYBN, REPL, PHAR, and SANA Company Descriptions

Cybin NYSE:CYBN

$7.17 -0.43 (-5.66%)

Closing price 04:00 PM Eastern

Extended Trading

$7.30 +0.13 (+1.81%)

As of 04:33 PM Eastern

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

Pharming Group NASDAQ:PHAR

$11.38 +0.13 (+1.16%)

Closing price 03:59 PM Eastern

Extended Trading

$11.34 -0.04 (-0.40%)

As of 04:24 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Replimune Group NASDAQ:REPL

$5.35 +0.26 (+5.11%)

Closing price 04:00 PM Eastern

Extended Trading

$5.35 +0.00 (+0.07%)

As of 04:32 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$3.43 +0.10 (+3.00%)

Closing price 04:00 PM Eastern

Extended Trading

$3.38 -0.05 (-1.31%)

As of 04:35 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time